RU2018127315A - Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний - Google Patents
Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний Download PDFInfo
- Publication number
- RU2018127315A RU2018127315A RU2018127315A RU2018127315A RU2018127315A RU 2018127315 A RU2018127315 A RU 2018127315A RU 2018127315 A RU2018127315 A RU 2018127315A RU 2018127315 A RU2018127315 A RU 2018127315A RU 2018127315 A RU2018127315 A RU 2018127315A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- dimethylcyclohex
- piperazin
- pyrrolo
- yloxy
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims 4
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 230000001900 immune effect Effects 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- -1 4 - {[2- (4-chlorophenyl) -4,4-dimethylcyclohex-1-en-1-yl] methyl} piperazin-1-yl Chemical group 0.000 claims 80
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims 4
- 208000003747 lymphoid leukemia Diseases 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000002471 spleen cancer Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- TYERRNIXCPPQQD-UHFFFAOYSA-N N-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C(C1=CC=CC=C1)(=O)NOC=1C=C2C(=NC=1)NC=C2 TYERRNIXCPPQQD-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781070P | 2013-03-14 | 2013-03-14 | |
| US61/781,070 | 2013-03-14 | ||
| US14/176,506 US20140275082A1 (en) | 2013-03-14 | 2014-02-10 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US14/176,506 | 2014-02-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015143917A Division RU2662812C2 (ru) | 2013-03-14 | 2014-02-21 | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018127315A true RU2018127315A (ru) | 2019-03-13 |
| RU2018127315A3 RU2018127315A3 (cg-RX-API-DMAC7.html) | 2021-10-05 |
Family
ID=51529947
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018127315A RU2018127315A (ru) | 2013-03-14 | 2014-02-21 | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний |
| RU2015143917A RU2662812C2 (ru) | 2013-03-14 | 2014-02-21 | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015143917A RU2662812C2 (ru) | 2013-03-14 | 2014-02-21 | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний |
Country Status (35)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| RU2014128010A (ru) | 2011-12-13 | 2016-02-10 | Бак Инститьют Фо Рисерч Он Эйджин | Способы улучшения средств консервативной терапии |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| PE20151727A1 (es) | 2013-03-14 | 2015-12-17 | Boehringer Ingelheim Int | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| SG10201902074UA (en) | 2013-10-04 | 2019-04-29 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| SG11201606239UA (en) | 2014-01-28 | 2016-08-30 | Buck Inst For Res On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| PT3119397T (pt) | 2014-03-19 | 2022-04-11 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama |
| EA031376B1 (ru) | 2014-09-12 | 2018-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Спироциклические ингибиторы катепсина с |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN104370905B (zh) * | 2014-10-22 | 2016-06-01 | 南京友杰医药科技有限公司 | Bcl-2抑制剂ABT-199的合成 |
| US10799574B2 (en) | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
| EP3209676A4 (en) * | 2014-10-24 | 2018-03-28 | Hpvvax, Llc | Cancer and skin lesion treatment |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| KR102787845B1 (ko) | 2015-09-14 | 2025-03-31 | 트웰브 테라퓨틱스, 아이엔씨. | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
| CA3006477A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| HK1256935A1 (zh) * | 2016-02-27 | 2019-10-04 | 哈普威克斯有限责任公司 | 使用疫苗治疗癌症或皮肤病变的方法和组合物 |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN109641897B (zh) * | 2016-09-01 | 2021-12-07 | 北京赛林泰医药技术有限公司 | Bcl-2选择性抑制剂及其制备和用途 |
| EP3565815B1 (en) * | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| EP4119560B1 (en) | 2017-04-18 | 2024-06-05 | Fochon Pharmaceuticals, Ltd. | Apoptosis-inducing agents |
| CN108658983B (zh) * | 2017-06-26 | 2019-12-20 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 |
| KR102751751B1 (ko) | 2018-01-10 | 2025-01-10 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| LT3788042T (lt) | 2018-04-29 | 2025-03-25 | Beigene Switzerland Gmbh | Bcl-2 inhibitoriai |
| CN110577525A (zh) * | 2018-06-11 | 2019-12-17 | 北京万全德众医药生物技术有限公司 | 一种维奈妥拉中间体的制备方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| MX2021004856A (es) * | 2018-10-29 | 2021-10-13 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2. |
| EP3978494A4 (en) * | 2019-05-24 | 2023-04-19 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | METHYL AND TRFLUOROMETHYL CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITORS |
| EP4136084A4 (en) | 2020-04-15 | 2023-11-01 | BeiGene, Ltd. | BCL-2 INHIBITOR |
| CN114057728A (zh) * | 2020-08-06 | 2022-02-18 | 北京诺诚健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| US20230301989A1 (en) * | 2020-08-21 | 2023-09-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating systemic lupus erythematosus |
| EP4298098A4 (en) * | 2021-02-01 | 2025-06-25 | Ascentage Pharma (Suzhou) Co., Ltd. | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS |
| CN113046433B (zh) * | 2021-03-19 | 2022-12-02 | 武汉大学 | 细胞因子il1f9在制备检测、预防和治疗肿瘤的产品中的应用 |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| JPH11512429A (ja) | 1995-09-15 | 1999-10-26 | ファルマシア・アンド・アップジョン・カンパニー | アミノアリールオキサゾリジノン ｎ−オキシド |
| WO1997029131A1 (en) | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| NZ508118A (en) | 1998-07-06 | 2003-07-25 | Bristol Myers Squibb Co | Heteroaryl substituted biphenyl sulfonamides useful as dual angiotensin endothelin receptor antogonists |
| DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| CA2395772C (en) | 1999-12-28 | 2010-09-28 | Eisai Co., Ltd. | Sulfonamide-containing heterocyclic compounds |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| CA2446719A1 (en) | 2001-06-06 | 2002-12-12 | Eli Lilly And Company | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| MY135609A (en) | 2002-02-26 | 2008-05-30 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| CN100404032C (zh) | 2002-02-26 | 2008-07-23 | 阿斯特拉曾尼卡有限公司 | 新型晶形抗癌化合物zd1839 |
| FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| TWI262077B (en) | 2002-04-29 | 2006-09-21 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
| ES2294494T3 (es) | 2004-04-19 | 2008-04-01 | Symed Labs Limited | Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados. |
| US7429661B2 (en) | 2004-07-20 | 2008-09-30 | Symed Labs Limited | Intermediates for linezolid and related compounds |
| JP5128948B2 (ja) | 2004-08-27 | 2013-01-23 | ニッポネックス インコーポレイテッド | 癌の治療のための新規な薬剤組成物 |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| FR2884821B1 (fr) | 2005-04-26 | 2007-07-06 | Aventis Pharma Sa | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| CN101175738B (zh) | 2005-05-12 | 2010-10-27 | 雅培制药有限公司 | 细胞凋亡促进剂 |
| WO2006124863A2 (en) | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| BRPI0611863B1 (pt) | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| CN101534904B (zh) | 2006-09-05 | 2013-11-06 | Abbvie公司 | 治疗血小板过量的bcl抑制剂 |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| ES2525229T3 (es) | 2007-02-15 | 2014-12-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolinas como ligandos de TAAR1 |
| WO2008124878A1 (en) | 2007-04-13 | 2008-10-23 | Cryptopharma Pty Ltd | Non-steroidal compounds |
| KR20100012031A (ko) | 2007-04-19 | 2010-02-04 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 모르폴리닐 화합물 |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| CA2701172A1 (en) | 2007-10-01 | 2009-04-09 | The Johns Hopkins University | Methods of treating neurological autoimmune disorders with cyclophosphamide |
| WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| US20090131363A1 (en) | 2007-10-26 | 2009-05-21 | Harbeson Scott L | Deuterated darunavir |
| CA2705294C (en) | 2007-11-16 | 2016-05-17 | Abbott Laboratories | Methods of treating arthritis by the administration of substituted benzenesulfonamides |
| WO2009073835A1 (en) | 2007-12-06 | 2009-06-11 | Abbott Laboratories | Oral compositions of abt-263 for treating cancer |
| KR20100113112A (ko) | 2008-01-15 | 2010-10-20 | 아보트 러보러터리즈 | 개선된 포유동물 발현 벡터 및 이의 용도 |
| LT2346495T (lt) | 2008-10-07 | 2016-10-10 | Astrazeneca Uk Limited | Farmacinė kompozicija 514 |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| CN106008322B (zh) | 2008-12-05 | 2018-09-04 | Abbvie 公司 | 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物 |
| WO2010077740A2 (en) | 2008-12-09 | 2010-07-08 | Cytokine Pharmasciences, Inc. | Novel antiviral compounds, compositions, and methods of use |
| GB2466622A (en) * | 2008-12-23 | 2010-06-30 | Trinity College Dublin | Alpha2-Adrenoceptor Ligands |
| US20120094963A1 (en) | 2008-12-23 | 2012-04-19 | of Queen Elizabeth near Dublin | Targeting prodrugs and compositions for the treatment of gastrointestinal diseases |
| RU2538965C2 (ru) | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
| MX2011007681A (es) | 2009-01-19 | 2011-08-08 | Abbott Lab | Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes. |
| US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| MX339469B (es) | 2009-05-26 | 2016-05-27 | Abbvie Bahamas Ltd | Agentes inductores de apotosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes. |
| TWI471321B (zh) | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| SG10201801794WA (en) * | 2010-10-29 | 2018-04-27 | Abbvie Inc | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| PH12013501006A1 (en) * | 2010-11-23 | 2022-03-30 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| NZ610151A (en) | 2010-11-23 | 2015-06-26 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
-
2014
- 2014-02-10 US US14/176,506 patent/US20140275082A1/en not_active Abandoned
- 2014-02-21 MX MX2018006817A patent/MX384490B/es unknown
- 2014-02-21 EP EP18172795.9A patent/EP3415514A1/en not_active Withdrawn
- 2014-02-21 CN CN201480015341.4A patent/CN105026394B/zh active Active
- 2014-02-21 ES ES14709488.2T patent/ES2689679T3/es active Active
- 2014-02-21 JP JP2016500337A patent/JP6449222B2/ja active Active
- 2014-02-21 BR BR112015021115-1A patent/BR112015021115B1/pt not_active IP Right Cessation
- 2014-02-21 UA UAA201509683A patent/UA120035C2/uk unknown
- 2014-02-21 PE PE2019001832A patent/PE20191555A1/es unknown
- 2014-02-21 PT PT14709488T patent/PT2970257T/pt unknown
- 2014-02-21 LT LTEP14709488.2T patent/LT2970257T/lt unknown
- 2014-02-21 RS RS20181029A patent/RS57750B1/sr unknown
- 2014-02-21 MY MYPI2015702574A patent/MY178821A/en unknown
- 2014-02-21 PL PL14709488T patent/PL2970257T4/pl unknown
- 2014-02-21 KR KR1020217005057A patent/KR20210021613A/ko not_active Ceased
- 2014-02-21 EP EP14709488.2A patent/EP2970257B1/en active Active
- 2014-02-21 MX MX2015011641A patent/MX360541B/es active IP Right Grant
- 2014-02-21 PE PE2015001909A patent/PE20151555A1/es active IP Right Grant
- 2014-02-21 CA CA3110552A patent/CA3110552A1/en active Pending
- 2014-02-21 RU RU2018127315A patent/RU2018127315A/ru unknown
- 2014-02-21 DK DK14709488.2T patent/DK2970257T3/en active
- 2014-02-21 HR HRP20181403TT patent/HRP20181403T8/hr unknown
- 2014-02-21 WO PCT/US2014/017751 patent/WO2014158528A1/en not_active Ceased
- 2014-02-21 HU HUE14709488A patent/HUE038983T2/hu unknown
- 2014-02-21 AU AU2014242104A patent/AU2014242104B2/en not_active Ceased
- 2014-02-21 SG SG11201507363UA patent/SG11201507363UA/en unknown
- 2014-02-21 SG SG10201908388U patent/SG10201908388UA/en unknown
- 2014-02-21 RU RU2015143917A patent/RU2662812C2/ru active
- 2014-02-21 KR KR1020157028733A patent/KR102260645B1/ko not_active Expired - Fee Related
- 2014-02-21 NZ NZ631701A patent/NZ631701A/en not_active IP Right Cessation
- 2014-02-21 CA CA2899041A patent/CA2899041A1/en not_active Abandoned
- 2014-02-21 CN CN201711191505.0A patent/CN107987075B/zh active Active
- 2014-02-21 SI SI201430867T patent/SI2970257T1/sl unknown
- 2014-03-12 TW TW103108809A patent/TWI675835B/zh not_active IP Right Cessation
- 2014-03-12 TW TW107143342A patent/TWI717662B/zh not_active IP Right Cessation
- 2014-03-12 AR ARP140100875A patent/AR095263A1/es not_active Application Discontinuation
- 2014-03-13 UY UY0001035406A patent/UY35406A/es not_active Application Discontinuation
-
2015
- 2015-07-01 US US14/789,449 patent/US20150299197A1/en not_active Abandoned
- 2015-07-19 IL IL240010A patent/IL240010B/en active IP Right Grant
- 2015-07-20 ZA ZA2015/05203A patent/ZA201505203B/en unknown
- 2015-09-03 GT GT201500248A patent/GT201500248A/es unknown
- 2015-09-11 CL CL2015002640A patent/CL2015002640A1/es unknown
- 2015-09-29 CR CR20150510A patent/CR20150510A/es unknown
-
2016
- 2016-09-27 US US15/276,872 patent/US10081628B2/en active Active
-
2018
- 2018-01-18 DO DO2018000026A patent/DOP2018000026A/es unknown
- 2018-02-07 CL CL2018000353A patent/CL2018000353A1/es unknown
- 2018-08-22 US US16/108,346 patent/US20180354952A1/en not_active Abandoned
- 2018-08-30 CY CY181100904T patent/CY1120862T1/el unknown
- 2018-09-06 AU AU2018226476A patent/AU2018226476C1/en not_active Ceased
- 2018-10-18 JP JP2018196401A patent/JP2019038820A/ja active Pending
-
2019
- 2019-03-11 IL IL265296A patent/IL265296A/en unknown
- 2019-12-09 US US16/707,777 patent/US20200331907A1/en not_active Abandoned
-
2020
- 2020-01-06 AR ARP200100026A patent/AR117768A2/es unknown
- 2020-07-09 JP JP2020118278A patent/JP2020180145A/ja active Pending
-
2021
- 2021-02-04 US US17/167,507 patent/US20210403467A1/en not_active Abandoned
- 2021-07-01 JP JP2021109903A patent/JP2021167330A/ja active Pending
- 2021-10-17 IL IL287315A patent/IL287315A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018127315A (ru) | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний | |
| JP2019038820A5 (cg-RX-API-DMAC7.html) | ||
| JP2016517406A5 (cg-RX-API-DMAC7.html) | ||
| RU2497822C2 (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| RU2012127760A (ru) | Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний | |
| RU2012127790A (ru) | Индуцирующие апоптоз агенты для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2012528178A5 (cg-RX-API-DMAC7.html) | ||
| RU2012156844A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2013527202A5 (cg-RX-API-DMAC7.html) | ||
| RU2011127232A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2013512900A5 (cg-RX-API-DMAC7.html) | ||
| IL288243B2 (en) | Heteroaryl-substituted pyridines and methods of use | |
| JP2013512899A5 (cg-RX-API-DMAC7.html) | ||
| RU2015141713A (ru) | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний | |
| HRP20151001T1 (hr) | Sredstva kao induktori apoptoze za lijeäśenje raka te imunih i autoimunih bolesti | |
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| JP2013528204A5 (cg-RX-API-DMAC7.html) | ||
| RU2017146661A (ru) | Замещенные пиридины и способ их применения | |
| JP2016512825A5 (cg-RX-API-DMAC7.html) | ||
| JP2017502940A5 (cg-RX-API-DMAC7.html) | ||
| JP2017530185A5 (cg-RX-API-DMAC7.html) | ||
| JP2014523851A5 (cg-RX-API-DMAC7.html) | ||
| RU2015150946A (ru) | Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения | |
| CA2600195A1 (en) | Combinations for the treatment of cancer | |
| RU2015116816A (ru) | Производное имидазола |